Pathogen-reduced red blood cell suspension in pediatric transfusion practice

Introduction. Pathogen reduction technologies in donor blood products have provided a preventive approach against a variety of hemotransmissive infections as well as prevention of donor leukocyte complications. However, while pathogen reduction in plasma and platelet concentrates is currently widespread, methods for reducing pathogens in red blood cell (RBC)-containing products are still being studied.

Aim: to analyze the transfusion results of a pathogen-reduced RBC suspension in patients with various oncological and hematological diseases as well as defects of the immune system in order to prevent transfusion transmission of cytomegalovirus infection.

Patients and methods. The results of transfusion therapy of a pathogen-reduced RBC suspension for the prevention of transfusion transmission of CMV infection in 27 patients who underwent transfusions during a long follow-up period are presented.

Results. A total of 27 patients received 167 transfusions of pathogen-reduced RBC suspension. Transfusion efficacy, assessed by hemoglobin increase, was dependent on the transfusion volume per body weight, but was independent of the storage time of the RBC suspension over the measured interval. The transfusions were effective and tolerated without complications.

Conclusion. The clinical use of pathogen-reduced RBC suspension is safe and provides sufficient clinical and laboratory efficacy.

1. Haass K.A., Sapiano M.R.P., Savinkina A., et al. Transfusion-Transmitted Infections Reported to the National Healthcare Safety Network Hemovigilance Module. Transfus Med Rev. 2019; 33(2): 84–91. DOI: 10.1016/j.tmrv.2019.01.001.

2. Kopolovic I., Ostro J., Tsubota H., et al. A systematic review of transfusionassociated graft-versus-host disease. Blood. 2015; 126(3): 406–14. DOI: 10.1182/blood-2015-01-620872.

3. Godbey E.A., Thibodeaux S.R. Ensuring safety of the blood supply in the United States: Donor screening, testing, emerging pathogens, and pathogen inactivation. Semin Hematol. 2019; 56(4): 229–35. DOI: 10.1053/j.seminhematol.2019.11.004.

4. Stramer, S., Dodd, R. Transfusion-transmitted emerging infectious diseases: 30 years of challenges and progress. Transfusion. 2013; 53: 2375–83.

5. Glynn S., Busch M., Dodd R., et al. Emerging infectious agents and the nation’s blood supply: responding to potential threats in the 21st century. Transfusion. 2013; 53: 438–54.

6. de Korte D., Curvers J., de Kort W., et al. Effects of skin disinfection method, deviation bag, and bacterial screening on clinical safety of platelet transfusions in the Netherlands. Transfusion. 2006; 46: 476–85.

7. Letowska M., Windyga J., Poglod R. Clinical effect of therapeutic plasma exchange (TPE) with Mirasol PRT-treated fresh frozen plasma in patients with acquired thrombotic thrombocytopenic purpura. Transfusion. 2013; 53(Suppl): 116A.

8. Lanteri M., Kleinman S., Glynn S., et al. Zika virus: a new threat to the safety of the blood supply with worldwide impact and implications. Transfusion. 2016; 56(7): 1907–14.

9. Klein H., Anderson D., Bernardi M., et al. Pathogen inactivation: making decisions about new technologies. Report of a consensus conference. Transfusion. 2007; 47(12): 2338–47.

10. Hayashi, H., Nishiuchi, T., Tamura, H., Takeda, K. Transfusion associated graft versus-host disease caused by leukocytefiltered stored blood. Anesthesiology. 1992; 79: 1419–21.

11. Akahoshi M., Takanashi M., Masuda M., et al. A case of transfusion associated graft versus host disease not prevented by white cell-reduction filters. Transfusion. 1992; 32: 169–72.

12. Mintz P. Cesium cessation? An advantage of pathogen reduction treatments. Transfusion. 2011; 51: 1369–76.

13. Alter H. Pathogen reduction: a precautionary principle paradigm. Transfusion Medicine Reviews. 2008; 22(2): 97–102.

14. Seltsam A. Pathogen inactivation of cellular blood products — an additional safety layer in transfusion medicine. Front Med. 2017; 4: 219.

15. Grégoire Y., Delage G., Custer B., et al. Cost-effectiveness of pathogen reduction technology for plasma and platelets in Québec: A focus on potential emerging pathogens. Transfusion. 2022; 62(6): 1208–17. DOI: 10.1111/trf.16926.

16. Schottstedt V., Blümel J., Burger R., et al. Human Cytomegalovirus (HCMV) — Revised. Transfus Med Hemother. 2010; 37(6): 365–75. DOI: 10.1159/000322141.

17. Kumukova I.V., Trakhtman P.E., Starostin N.N., et al. Comparison of laboratory parameters of X-ray irradiated erythrocyte suspensions and suspensions, prepared from whole blood pre-treated with ultraviolet in the presence of ribofl avin. Voprosy Gematologii /Onkologii I Immunopatologii v Pediatrii. 2018; 17(1): 64–74 (In Russian). DOI: 10.24287/1726-1708-2018-17-1-64-74

18. Kumukova I., Trakhtman P., Starostin N., et al. Quality assessment of red blood cell suspensions derived from pathogen-reduced whole blood. Vox Sang. 2021; 116(5): 547–56. DOI: 10.1111/vox.13039.

19. Trakhtman P., Kumukova I., Starostin N., et al. The pathogen-reduced red blood cell suspension: single centre study of clinical safety and efficacy in children with oncological and haematological diseases. Vox Sang. 2019; 114(3): 223–31. DOI: 10.1111/vox.12757.

20. Kumukova I.B., Trakhtman P.I., Starostin N.N., et al. Results of clinical application of pathogen-reduced red blood cell suspension in children with oncological and hematological diseases. Voprosy Gematologii/Onkologii I Immunopatologii V Pediatrii. 2018; 17(4): 43–50 (In Russian). DOI: 10.24287/1726-1708-2018-17-4-43-50.

21. Kumukova I., Starostin N., Trakhtman P. Universal pathogen reduction in blood components is a close perspective. Vox Sang. 2021;116(6):735–6. DOI: 10.1111/vox.13093.